TARAProtara TherapeuticsSigning up patients
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +3.3
A key executive is leaving
Since Jun 29, 2026 · was worth 15, fading over time
Worry score3
Score over time
- Stage
- Phase 2
- Patients
- 131 (planned)
- Started
- Sep 15, 2023
- Main results expected
- Oct 2031
- Fully finished
- Mar 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002
Measured over: Month 3 to Month 60
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 3.3, since 2026-06-29, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT05951179 · record last updated 2026-08-24 · checked 2026-11-09 15:47 UTC